Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corp (ABSI) combines generative AI with synthetic biology to accelerate therapeutic discovery. This news hub provides investors and industry professionals with essential updates on the company's advancements in AI-driven drug development, strategic collaborations, and platform innovations.
Access verified press releases covering key milestones including research breakthroughs, partnership announcements, and financial developments. Our curated collection enables efficient tracking of Absci's progress in optimizing biologic drug creation through its Integrated Drug Creation™ platform.
Explore updates across critical categories: AI technology enhancements, pharmaceutical partnerships, therapeutic pipeline developments, and financial performance. Each update maintains factual accuracy while highlighting Absci's unique position at the intersection of computational biology and drug discovery.
Bookmark this page for direct access to primary source materials and official announcements. Regularly updated content ensures stakeholders stay informed about Absci's contributions to oncology, immunology, and next-generation biologic therapies.
Absci (NASDAQ: ABSI) reported new human ex vivo data for ABS-201, an anti‑PRLR antibody, showing it prolongs anagen, stimulates hair matrix keratinocyte proliferation, increases follicular IGF1 and FGF7, and preserves/expands the K15+/CD34+ stem and progenitor pool in organ‑cultured full‑thickness human scalp. Findings suggest ABS-201 may reverse follicle miniaturization by promoting vellus‑to‑terminal reconversion and neutralizing intrafollicular prolactin signaling. The full dataset was presented at Absci’s ABS-201 KOL seminar on Dec 11, 2025 and slides were posted to investor relations.
Absci (Nasdaq: ABSI) announced a partnership with U.S. soccer legend Landon Donovan to raise awareness of androgenetic alopecia (AGA) and the emotional impact of hair loss. Donovan will speak about his personal experience at Absci’s virtual Key Opinion Leader seminar on December 11, 2025, providing patient perspective to guide development of the company’s investigational antibody ABS-201. Absci said it will present additional human ex vivo data supporting the PRLR mechanism of action and discuss the anticipated clinical development path and market opportunity for ABS-201.
The collaboration aims to destigmatize hair loss, highlight unmet treatment needs, and center patient voice in Absci’s AI-driven drug design efforts.
Absci (Nasdaq: ABSI) announced dosing of the first healthy volunteers in the Phase 1/2a HEADLINE trial of ABS-201, an AI-designed anti-prolactin receptor antibody for androgenetic alopecia (AGA).
The randomized, double-blind, placebo-controlled study will enroll up to 227 participants, assess safety, tolerability, PK/PD, immunogenicity and efficacy (TAHC, TAHW, TAHD), and includes SAD (4–6 IV dose groups) and MAD (3–4 SC dose groups) stages. Interim AGA data are expected in H2 2026. Absci plans to start Phase 2 in endometriosis in Q4 2026 with an interim endometriosis readout planned for H2 2027. A KOL seminar is scheduled for Dec 11, 2025.
Absci (Nasdaq: ABSI) reported Q3 2025 results and program updates. Key financials: revenue $0.4M (Q3 2024: $1.7M), net loss $28.7M, and cash, cash equivalents & marketable securities $152.5M, which the company says is sufficient to fund operations into the first half of 2028.
Clinical highlights: interim Phase 1 data for ABS-101 showed extended half-life and no serious adverse events. ABS-201 (anti-PRLR) will start a Phase 1/2a in Dec 2025 with a potential interim efficacy readout in H2 2026 and an expanded Phase 2 in endometriosis expected in Q4 2026 with potential POC in H2 2027. Company to host a KOL seminar on Dec 11, 2025.
Absci (Nasdaq: ABSI) will report business updates and third quarter 2025 financial and operating results after market close on Wednesday, November 12, 2025.
Management will host a webcast and conference call on November 12, 2025 at 4:30 p.m. ET (1:30 p.m. PT) to discuss developments, results, and outlook. Live audio will stream on the company investor relations site at investors.absci.com, and the webcast will be archived for replay after the event.
Absci (Nasdaq: ABSI) announced participation in three investor conferences in November 2025: a Guggenheim Securities fireside chat and 1x1 meetings on Nov 10, 2025 at 10:00 AM ET; UBS Global Healthcare 1x1 meetings on Nov 11, 2025; and a Jefferies Global Healthcare presentation and 1x1 meetings on Nov 18, 2025 at 9:30 AM GMT (4:30 AM ET).
Live and archived webcasts of the Guggenheim and Jefferies sessions will be available on Absci’s investor relations site at investors.absci.com.
Absci (Nasdaq: ABSI) will host a virtual seminar on December 11, 2025 at 10:00 a.m. ET to discuss its ABS-201 (anti-PRLR) program for androgenetic alopecia with leading dermatology KOLs.
The company now expects to initiate the Phase 1/2a trial in early December 2025, ahead of prior guidance for early 2026, with an interim efficacy readout anticipated in the second half of 2026. The seminar will include presentations and a live Q&A; registration and archived webcast will be available at investors.absci.com.
Absci (NASDAQ:ABSI) has announced a strategic collaboration with Oracle Cloud Infrastructure (OCI) and AMD to enhance its AI-driven drug discovery platform. The partnership leverages OCI's AI infrastructure and AMD's latest hardware, including next-generation Instinct™ MI355X GPUs, to accelerate biologics design cycles and reduce costs.
The collaboration enables Absci to perform large-scale molecular-dynamics simulations and end-to-end antibody design with improved efficiency. Using OCI's bare metal instances powered by 5th Generation AMD EPYC™ processors, Absci has achieved ultra-low latency of 2.5 µs and terabytes-per-second throughput for data processing.
Absci (Nasdaq: ABSI) has strengthened its ABS-201 Scientific Advisory Board by adding two prominent dermatology experts, Dr. Rodney Sinclair and Dr. David Goldberg. The experts will guide the development of ABS-201, an AI-designed therapeutic antibody for androgenetic alopecia treatment.
ABS-201 targets prolactin receptors to stimulate hair follicle regeneration and has shown superior hair regrowth compared to minoxidil in preclinical mouse models. The company plans to initiate Phase 1/2a clinical trials in early 2026, with initial proof-of-concept data expected in H2 2026.
The condition affects approximately 80 million Americans, with current FDA-approved treatments showing limited efficacy and notable side effects. Both new advisors bring extensive experience in dermatology and hair loss research, with Dr. Sinclair having authored over 1,000 publications and Dr. Goldberg having participated in the original Minoxidil trials.
Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company focused on AI-driven therapeutic development, has announced its participation in three major upcoming investor conferences in September 2025.
The company will attend the 2025 Wells Fargo Healthcare Conference in Boston for one-on-one meetings on September 3, the Morgan Stanley 23rd Annual Global Healthcare Conference in New York for a fireside chat on September 8, and the H.C. Wainwright 27th Annual Global Investment Conference in New York for a fireside chat on September 9. Webcasts for the Morgan Stanley and H.C. Wainwright sessions will be available on Absci's investor relations website.
FAQ
What is the current stock price of Absci (ABSI)?
What is the market cap of Absci (ABSI)?
